ClinicalTrials.gg
Not yet recruitingNCT07571135Updated May 8, 2026

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

A Phase 4 interventional study of Letermovir and Valganciclovir CMV Prophylaxis in CMV Infection, CMV and CMV Viremia, sponsored by Elisabeth Kincaide. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Elisabeth Kincaide · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Planned enrollment
2nd of 17
300 · median 80
Started
2026
the only one that year
Phase 4
4 of 17
2 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Elisabeth Kincaide

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 4, and was the 17th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive. To do this, researchers will compare patients who received letermovir with a group of historical patients who received valganciclovir ("mini dose"). Both groups will be on CMV prophylaxis drug for 90 days post-transplant.

The main question the study wants to answer is:

  • Does letermovir work as well as valganciclovir in preventing CMV infections during the first 12 months after a kidney transplant?

The study will also look at other important questions:

  • Is letermovir easier for patients to tolerate than valganciclovir?
  • How long does it take for a CMV infection to appear in each group?
  • Are there differences in "breakthrough" CMV infections between the two medications?
  • For patients who develop CMV that becomes resistant to treatment, are the resistance patterns different between the two groups
Read the detailed description

The purpose of this study is to evaluate the efficacy and tolerability of letermovir compared to standard-of-care, valganciclovir, for the prevention of clinically significant cytomegalovirus (CMV) infection in CMV moderate risk adult kidney transplant recipients.

A 3:1 match of historical valganciclvoir:letermovir arm

  • Matching criteria:
  • Induction agent: lymphocyte-depleting (rabbit anti-thymocyte globulin or alemtuzumab) versus non-lymphocyte depleting (basiliximab)
  • Delayed graft function (dialysis within one week of kidney transplant)
  • MMF dose at de novo discharge (weight-based vs non-weight based)

Study Arms:

  • Letermovir Arm:

    • Letermovir 480 mg PO daily starting POD 4 through 10 OR
    • Letermovir 240 mg PO daily if given concomitantly with cyclosporine, for 90 days
    • Will be given with acyclovir 400 mg PO BID (or 200 PO BID if CrCl \<25) for 90 days
  • Historical Arm:

    • Valganciclovir 450 mg PO daily (adjusted for renal function) for 90 days

      • CrCl 25-30: valganciclovir 450 mg PO q 48 h
      • CrCl \<25: Valganciclovir 450 mg PO three times weekly

Outcomes:

  • Primary Efficacy Objective:

    • Incidence of patients with clinically significant CMV infection at 12 months post kidney transplant in patients who received letermovir versus standard of care valganciclovir

      • Clinically Significant CMV Infection: CMV disease or symptomatic viremia requiring therapeutic intervention
  • Secondary Objectives:

    • Tolerability:

      • Proportion of patients with leukopenia or neutropenia (composite) in patients who received letermovir versus standard of care valganciclovir
  • Leukopenia: white blood cells \< 3500 cells/uL
  • Neutropenia: absolute neutrophil count \< 1000 cells/uL

    • Intolerability or early drug discontinuation
  • Proportion of patients who discontinue the study drug prematurely due to adverse events or intolerance

    o Efficacy:

    • Time-to clinically significant CMV infection (days)
    • Breakthrough CMV while on CMV prophylaxis
  • CMV Viremia

    • Detection of CMV DNA in blood via PCR
  • Clinically significant CMV infection

    • CMV resistance
  • Detection of CMV strains with genotypic or phenotypic resistance to antiviral agents used in prophylaxis or treatment
03

Conditions studied

  • CMV Infection
  • CMV
  • CMV Viremia
  • CMV Disease

Keywords

  • CMV
  • Kidney Transplant
  • Letermovir
  • Moderate Risk
  • CMV Prophylaxis
  • Valganciclovir
  • Neutropenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (both arms):

  • ≥18 years old
  • Kidney transplant recipient with documented CMV IgG seropositive status (R+) within 90 days prior to transplant

Inclusion Criteria (letermovir arm):

  • Males agree to use and refraining from donating sperm for 290 days post-treatment initiation
  • Females of agree to follow contraception guidance for 290 days post-treatment initiation

Exclusion Criteria (both arms):

  • Multiorgan organ transplant
  • Received previous solid organ transplant or
  • Unable to take oral medications
  • Uncontrolled infections at the time of enrollment
  • Hemodynamically unstable or on mechanical ventilation at the time of enrollment
  • Documented or detectable 90 days prior to enrollment or HCV+ donor
  • Pregnant or breastfeeding or planning to be pregnant, breastfeeding or donating eggs during study period and 90 days post cessation
  • Received any anti-CMV drug treatment within 7 days prior to enrollment
  • Current user of recreational or illicit drugs or alcohol dependence
  • History of CMV disease prior to enrollment

Exclusion Criteria (letermovir arm):

  • Previously participated in a letermovir study or any other study with CMV agents
  • On dialysis or plasmapheresis at the time of enrollment
  • Known or suspected to active or inactive ingredients from letermovir or acyclovir formulations
  • Class C severe hepatic insufficiency
  • Currently participating or has participated in a study with an unapproved compound of device within 28 days or 5 half-lives of this study
  • per letermovir or acyclovir package insert: patients on pimozide, ergot alkaloids; or pitavastatin and simvastatin when co-administered with cyclosporine
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Letermovir

    Prospective letermovir prophylaxis

    Drug: Letermovir

  • Other
    Valganciclovir

    Historical valganciclovir prophylaxis

    Drug: Valganciclovir CMV Prophylaxis

Interventions

  • Letermovir 480 mg PO daily or 240 mg PO daily (if on cyclosporine) for 90 days post kidney transplant

  • DrugValganciclovir CMV Prophylaxis

    Valganciclovir 450 mg PO daily for 90 days post kidney transplant (Historical Control)

06

What researchers measure

Primary outcomes

  1. CMV Infection

    Incidence of patients with clinically significant CMV infection at 12 months post kidney transplant in patients who received letermovir versus standard of care valganciclovir.

    Time frame: 12 months post kidney transplant

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Nov 2028, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartEst.
May 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07571135
Lead sponsor
Elisabeth Kincaide
Responsible party
Elisabeth Kincaide (Principle Investigator, Solid Organ Transplant Clinical Pharmacy Specialist, Adjoint Assistant Professor, Bexar County Hospital District dba University Health) — Sponsor-investigator
First posted
May 6, 2026
Start date
May 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
May 8, 2026

Study contacts

Elisabeth Kincaide, PharmD
Contact
Elisabeth.Kincaide@uhtx.com
210-743-4086
Sean Moore, BSN, RN
Contact
Sean.Moore2@uhtx.com
210-475-2559

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion